FENC Q1 2024 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$25M+1413.2% YoY

Gross Profit

$25M97.8% margin

Operating Income

$14M54.2% margin

Net Income

$13M50.6% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+153.7%

Cash Flow

Operating Cash Flow

$39M

Free Cash Flow

$39M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$69M

Total Liabilities

$66M

Stockholders' Equity

$3M

Cash & Equivalents

$51M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$25M	$2M	+1413.2%
Gross Profit	$25M	$2M	+1469.3%
Operating Income	$14M	-$5M	+360.8%
Net Income	$13M	-$6M	+312.1%